Summit Therapeutics (SMMT) Operating Expenses (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Operating Expenses came in at $220.5 million in Q2 2026, down 61.21% YoY from $568.4 million in Q2 2025, and up 12.95% on a QoQ basis from $195.2 million in Q1 2026.
Summit Therapeutics (SMMT) Operating Expenses (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Operating Expenses data on file, last reported at $220.5 million in Q2 2026.
- Quarterly Operating Expenses fell 61.21% year-over-year to $220.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $874.8 million (up 15.22% YoY) and the FY2025 annual result came in at $1.1 billion, up 384.26% from the prior year.
- Operating Expenses rose to $220.5 million in Q2 2026, from $195.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $568.4 million in Q2 2025 to a low of $15.8 million in Q2 2023.
- A 5-year average of $135.2 million and a median of $59.0 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2023 — Operating Expenses jumped 1875.89% — and 2024, when it tumbled 92.12%.
- Tracing SMMT's Operating Expenses over 5 years: stood at $21.4 million in 2022, then soared by 65.12% to $35.4 million in 2023, then soared by 85.41% to $65.6 million in 2024, then soared by 242.8% to $224.9 million in 2025, then declined by 1.97% to $220.5 million in 2026.
- The last three Operating Expenses figures came in at $220.5 million (Q2 2026), $195.2 million (Q1 2026), and $224.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 220.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220.50 Mn |
| Mar 31, 2026 | 195.21 Mn |
| Dec 31, 2025 | 224.93 Mn |
| Sep 30, 2025 | 234.21 Mn |
| Jun 30, 2025 | 568.44 Mn |
| Mar 31, 2025 | 66.85 Mn |
| Dec 31, 2024 | 65.61 Mn |
| Sep 30, 2024 | 58.38 Mn |
| Jun 30, 2024 | 59.62 Mn |
| Mar 31, 2024 | 42.39 Mn |
| Dec 31, 2023 | 35.39 Mn |
| Sep 30, 2023 | 20.76 Mn |
| Jun 30, 2023 | 15.77 Mn |
| Mar 31, 2023 | 537.74 Mn |
| Dec 31, 2022 | 21.43 Mn |
| Sep 30, 2022 | 22.62 Mn |
| Jun 30, 2022 | 15.94 Mn |
| Mar 31, 2022 | 27.22 Mn |
| Dec 31, 2021 | 30.89 Mn |
| Sep 30, 2021 | 25.61 Mn |